Wechselwirkungen · Nimvastid
Nimvastid 1.5 mg orodispersible tablets Nimvastid 3 mg orodispersible tablets Nimvastid 4.5 mg orodispersible tablets Nimvastid 6 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-210217 · Präparat HOS-154463
Additive effects leading to bradycardia (which may result in syncope) have been reported with the combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta- blockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-17T12:40:00Z · SHA-256 7977a2e740f93e10c6c1dbfee473c4849225e6d1d135ce94de2c91c369b45b63 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 556–1112 im Abschnitt